ProfileGDS5678 / 1416744_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 62% 62% 60% 62% 66% 66% 63% 68% 62% 63% 62% 63% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8760864
GSM967853U87-EV human glioblastoma xenograft - Control 23.7191262
GSM967854U87-EV human glioblastoma xenograft - Control 33.7229362
GSM967855U87-EV human glioblastoma xenograft - Control 43.5747360
GSM967856U87-EV human glioblastoma xenograft - Control 53.65362
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0287266
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0439866
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7549863
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1586568
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6709162
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7530763
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6498762
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7762863
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7414563